Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Randy Guggenheimer Joins Burrill Merchant BankingJanuary 04, 2007
San Francisco, CA - January 04, 2007
Burrill & Company, a San Francisco-based global leader in life sciences with principal activities in Venture Capital, Merchant Banking and Media today announced that Randolph ("Randy") Guggenheimer III has joined the firm as Managing Director, Merchant Banking. Randy will assist clients in structuring, negotiating and completing merger and acquisition, licensing, and other transactions. Randy brings over 20 years of investment banking experience in the healthcare and life sciences industries.
Randy worked for over 15 years at Lehman Brothers, where he completed over 40 advisory transactions in the healthcare and life sciences sectors, ranging in size from $40 million to over $2 billion. He served as Managing Director in the Healthcare Group, Managing Director in the Mergers and Acquisitions Group, and Co-Head of Healthcare Mergers and Acquisitions.
Prior to joining Burrill & Company, Randy was Managing Director and Head of Healthcare Investment Banking for the Americas at Dresdner Kleinwort.
Randy graduated from Harvard College and earned an MBA from Harvard Business School.
"We are delighted to have Randy on board. His broad experience in healthcare investment banking and track record of strategic advice to biotechnology and pharmaceutical companies is a perfect fit with Burrill," said G. Steven Burrill, CEO of Burrill & Company.
James Watson, Head of Merchant Banking said, "Randy joins a rapidly growing team and will enhance our merger and acquisition capabilities as well as our presence on the east coast of the USA."
About Burrill Merchant Banking
Burrill Merchant Banking assists life science companies to identify, negotiate and close strategic transactions. Service lines include:
- Merger & Acquisitions across life sciences
- Strategic Partnering from early-stage research, to product development and commercialization
- Spin-Outs and Divestitures to create a new company or build value in an established entity
- Financing Advisory and Private Placement
- Advisory Services defining the role of transactions in achieving strategic objectives
Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with principal activities in Venture Capital, Merchant Banking and Media. It has over $725 million in venture capital funds under management and has completed numerous merchant banking transactions. The company¹s 50 person scientific and business team, supported by its nearly 40-person Advisory Boards, the strategic and financial network of its limited partners, and the close relationships developed with numerous life science companies and management, provide Burrill with unparalleled access and insight.
The company’s Media Group publishes an annual book on the "State of the Industry" the 20th Edition is Biotech 2006-Life Sciences: A Changing Prescription. Burrill also publishes a range of biotechnology/life science newsletters and reports and is also the sponsor and facilitator of over a dozen leading industry conferences. Full details may be found at: http://www.burrillandco.com/
For more information please contact James Watson, Managing Director, Head of Merchant Banking at firstname.lastname@example.org Back to News list